Co-creation and iterative needs assessment with patients and healthcare providers in an International phase II TILs therapy trial (PRAGMATIL)
Por:
Cacilhas, P, Malagrida, R, Gillanders, E, Kuld-Nielsen, A, Everhard, S, Monras, M, Alberú, XV, Le Moal, F, Garralda, E, Aguiar, VG, García-Lema, J, Zuazua-Schücker, E, Vaz-Luis, IV, Vives-Adrián, L and Franzoi, MA
Publicada:
1 sep 2025
Ahead of Print:
1 sep 2025
Resumen:
Filiaciones:
Cacilhas, P:
Inst Gustave Roussy, Canc Survivorship Grp, INSERM 981, Villejuif, France
:
Fdn IrsiCaixa, IrsiCaixa, Badalona, Spain
Gillanders, E:
Inst Gustave Roussy, Canc Survivorship Grp, INSERM 981, Villejuif, France
Kuld-Nielsen, A:
Herlev Hosp, Natl Ctr Canc Immune Therapy CCIT DK, Dept Oncol, Herlev, Denmark
Everhard, S:
Unicancer, Data & Partnerships Dept, Paris, France
Monras, M:
Vall dHebron Inst Oncol VHIO, Vall dHebron Inst Oncol, Barcelona, Spain
Alberú, XV:
Vall dHebron Inst Oncol VHIO, Vall dHebron Inst Oncol, Barcelona, Spain
Le Moal, F:
Seintinelles, Paris, France
Garralda, E:
Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
Aguiar, VG:
Vall dHebron Univ Hosp, Early Clin Drug Dev Grp, Barcelona, Spain
García-Lema, J:
La Caixa Fdn, Barcelona, Spain
Zuazua-Schücker, E:
La Caixa Fdn, Barcelona, Spain
Vaz-Luis, IV:
Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
Vives-Adrián, L:
Fdn IrsiCaixa, IrsiCaixa, Badalona, Spain
Franzoi, MA:
Inst Gustave Roussy, Canc Survivorship Grp, INSERM 981, Villejuif, France
Bronze
|